Chounta, Vasiliki
Snedecor, Sonya J.
Wu, Sterling
Van de Velde, Nicolas
Clinical trials referenced in this document:
Documents that mention this clinical trial
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)
https://doi.org/10.1007/s40271-021-00524-0
Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection
https://doi.org/10.1186/s12879-022-07243-3
Documents that mention this clinical trial
Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection
https://doi.org/10.1186/s12879-022-07243-3
Documents that mention this clinical trial
Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection
https://doi.org/10.1186/s12879-022-07243-3
Funding for this research was provided by:
ViiV Healthcare
Article History
Received: 4 September 2020
Accepted: 4 March 2022
First Online: 4 May 2022
Declarations
:
: This study is a statistical analysis of data from the ATLAS, FLAIR and ATLAS-2M trials and therefore does not require approval from an institutional review board or ethics committee. All data included within this analysis are aggregated data from previously conducted clinical trials, no individual participant data were analyzed. As these studies were supported by ViiV Healthcare, no additional administrative permissions were required to access the data included in this study.
: Not applicable.
: VC and NV are employees of ViiV Healthcare. SW is employee of GlaxoSmithKline and owns stocks/shares. SJS is an employee of Pharmerit– an OPEN Health Company, paid consultants to ViiV Healthcare.